A coalition of ALS patients, caregivers, and advocates has submitted a citizens’ petition to the FDA, requesting approval of NurOwn (debamestrocel)—a stem-cell therapy developed for amyotrophic lateral sclerosis (ALS). Their push comes amid growing frustration over burocratic delays and mounting real-world data indicating potential patient benefits.
🚨 What Is NurOwn—and Why Does It Matter?
NurOwn is an autologous stem-cell treatment: doctors collect a patient’s own bone marrow mesenchymal stem cells (MSCs), grow them into MSC-NTF cells in a lab, and inject them into the spinal canal to promote nerve-cell survival and dampen inflammation .
Its development encountered early setbacks—a 200-patient Phase 3 trial failed to meet its primary goals, and an FDA advisory committee voted 17–1 against approval in 2023, citing insufficient evidence of efficacy . But advocates argue the real-world results tell a fuller story.
Real Patients, Real Results
Within the pharmaceutical world, trial statistics often take center stage—but ALS patients highlight the power of expanded access program (EAP) data:
9 of 10 EAP participants survived beyond five years after symptom onset—far above the expected ~10% rate. Median survival was 6.8 years . Subgroup analyses of less-advanced patients (ALSFRS‑R ≥ 35) saw statistically significant functional benefits, with roughly 2 extra points preserved on a key disability scale versus placebo . Individual stories—like that of Navy veteran Matt Bellina—describe increased strength, improved breathing, and better quality of life after receiving NurOwn through Right-to-Try or EAP programs .
The Petition: What Advocates Are Asking
Filed in early July, the petition requests that the FDA:
Reassess all accumulated data—from clinical trials and real-world EAP outcomes. Consider conditional approval or accelerated approval pathways under post-marketing Phase IV surveillance—especially given the disease’s rapid progression and lack of alternatives . Prioritize urgency for patients, arguing ALS is as terminal as many cancers and deserves similar regulatory flexibility .
As one patient wrote:
“ALS is stealing decades from our lifespans … Please don’t let another generation die waiting when we know a stem cell therapy can help us live.”
Biotech Stance & Next Steps
BrainStorm Cell Therapeutics—the company behind NurOwn—has distanced itself from drafting the petition but publicly supports the FDA review process. The company is moving ahead with a Phase 3b (ENDURANCE) trial, under an FDA Special Protocol Assessment (SPA), in hopes of delivering stronger proof while real-world access expands .
Meanwhile, the FDA remains cautious. Experts in internal memoranda have warned about trial failures, low-quality control reporting, and weak statistical significance in the original submission . Yet recent agency comments on regulatory flexibility for rare disease drugs leave room for possible compromise.
High Stakes for an ALS Community
ALS destroys motor function rapidly—most patients die within 3–5 years of diagnosis, and few approved treatments exist to slow decline. Patients involved in the petition emphasize that urgent access—even if limited—could mean priceless time and autonomy:
Advocates like Nick Warack and Dr. Danielle Geraldi‑Samara stress dose-dependent responses and clinical anecdotes from their practice showing preserved breathing and mobility in treated patients . Families like that of Matt Klingenberg describe “tracheostomy-free survival” beyond five years—virtually unheard of in standard ALS progression .
Opponents warn that lowering approval standards could endanger regulatory credibility. The debate centers on balancing hope and urgency with the FDA’s mission to ensure safety, efficacy, and high-quality evidence.
What Lies Ahead
With a decision timeline for NurOwn approval still open, the FDA faces a critical crossroads:
Grant conditional or accelerated approval alongside Phase IV studies? Many advocates hope so. Or wait years for Phase 3b data, potentially closing the therapy’s window for many patients?
As ALS advocates continue to mobilize petitions, letters, and public comment, one thing is clear: this is more than a drug approval fight—it’s a battle over how science, regulation, and humanity intersect in rare disease care.